The association of HPV in oropharyngeal cancer has identified a ‘new disease’, with its unique biologic behaviour, and challenges for clinicians in selecting therapeutic combinations offering maximum efficacy and minimum morbidity or long-term sequela currently under study in clinical trials....
9 September 2020
| Michal Luntz, Emma Stapleton
|
ENTA - Otology
Professor Michal Luntz is an Otologist and Cochlear Implant Surgeon, and Director of the Ear and Hearing Center in A.R.M, Assuta Tel Aviv, Israel. We caught up with her to hear about her life, her background, and her unique insight...
Ukrainian ENT teams continue life-saving and routine care under air raid alerts, with staff shortages, strained resources and the long psychological toll of war. War reshapes medicine long before it destroys hospitals. It alters the rhythm of clinical work, the...
Patients with conductive or mixed hearing loss become candidates for amplification when reconstructive surgery is not viable. Three common amplification options are conventional acoustic devices, such as behind-the-ear devices (BTEs), (implantable) bone-conduction devices and active middle ear implants. The goal...